文献速递神经肿瘤

单次立体定向放射外科作为散发性脑膜瘤主要治疗:25年队列研究

Single-Fraction Stereotactic Radiosurgery as Primary Management of Sporadic Meningiomas: A 25-Year Cohort Study.
PubMed 文献 · Neurosurgery · 2025-06-06

结果显示5年、10年、15年无进展生存率分别为99.8%、99.0%、93.2%,治疗相关并发症发生率为9.1%,其中永久性/需干预的并发症仅1.0%。SRS对中小体积散发性脑膜瘤有效且安全。

要点

  • 单次SRS治疗散发性脑膜瘤的15年PFS达93.2%,失败率仅1.4%。
  • 治疗相关并发症9.1%,永久性/需干预并发症仅1.0%。
  • 对于偶然发现的小体积脑膜瘤,可讨论早期SRS作为观察外的安全选择。

核心结论

  • SRS是散发性中小体积颅内脑膜瘤的有效主要治疗方式。
  • 对于偶然发现的脑膜瘤,可讨论早期SRS作为优于单纯观察的安全策略。

研究设计与样本

  • 中位随访6.3年(IQR 3.1-10.5年),中位肿瘤体积4.5 cm³(IQR 2.0-8.0 cm³),中位边缘剂量15.0 Gy(IQR 14.0-16.0 Gy)。

主要发现

  • 野内进展7个肿瘤(1.1%),边缘进展2个肿瘤(0.3%),总失败率1.4%。
  • 5年、10年、15年PFS分别为99.8%、99.0%、93.2%。
  • 治疗相关并发症56例(9.1%),其中暂时性45例(7.3%),轻微5例(0.8%),永久性和/或需干预6例(1.0%)。

临床怎么用

  • 对于散发性中小体积脑膜瘤,单次SRS可作为主要治疗选择,局部控制率高且永久性并发症风险低。
  • 治疗计划中应关注等中心数、12Gy体积和肿瘤体积以降低并发症风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Stereotactic radiosurgery (SRS) is increasingly used as a primary treatment modality for intracranial meningiomas. We aim to describe clinical outcomes after single-fraction SRS for sporadic intracranial meningiomas. METHODS: A prospectively maintained database was reviewed for patients with sporadic meningiomas who underwent SRS (Gamma Knife) as primary treatment modality from April 1997 to February 2022. Primary outcomes included progression-free survival (PFS) and treatment-related complications. RESULTS: Six hundred sixteen patients (653 tumors) underwent SRS with median follow-up of 6.3 years (interquartile range [IQR] 3.1-10.5 years). The median tumor volume was 4.5 cm 3 (IQR 2.0-8.0 cm 3 ). The median margin dose was 15.0 Gy (IQR 14.0-16.0). In-field progression was noted in 7 tumors (1.1%) and marginal progression in 2 tumors (0.3%) for a raw failure rate of 1.4%. PFS estimates at 5, 10, and 15 years were 99.8%, 99.0%, and 93.2%, respectively. Factors associated with reduced PFS on univariable analysis included older age (hazards ratio [HR] 1.14, 95% CI, 1.05-1.22, P < .001), male sex (HR 5.44, 95% CI, 1.45-20.4, P = .010), increasing tumor volume (HR 1.06, 95% CI, 0.99-1.13, P = .028), and lower tumor margin dose (HR 0.65, 95% CI, 0.43-0.97, P = .006). Treatment-related complications were noted in 56 patients (9.1%), of which 45 (7.3%) were temporary, 5 (0.8%) were minor, and 6 (1.0%) were permanent and/or required intervention. Radiosurgical parameters associated with treatment-related complications included increased number of isocenters (odds ratio [OR] 1.09, 95% CI, 1.04-1.14, P < .001), higher 12-Gy volume (OR 1.06, 95% CI, 1.03-1.09, P < .001), larger tumor volume (OR 1.06, 95% CI, 1.02-1.10, P < .001), and lower maximal dose (OR 0.90, 95% CI, 0.82-0.98, P = .11). CONCLUSION: SRS is effective as a primary treatment modality for sporadic, small-volume to medium-volume intracranial meningiomas. Pre-emptive SRS should be discussed as a safe management strategy compared with observation alone for incidentally discovered meningiomas.

来源:Neurosurgery,查看原文。版权归原作者所有。

引用

  1. Kumar R, Carlstrom LP, Morshed R, et al. Single-Fraction Stereotactic Radiosurgery as Primary Management of Sporadic Meningiomas: A 25-Year Cohort Study. Neurosurgery. 2025. PMID: 40476726. doi:10.1227/neu.0000000000003528

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。